![Peter Moldt](data:image/svg+xml,<svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" fill="%231b1b1b" class="bi bi-person-fill" viewBox="0 0 16 16"><path d="M3 14s-1 0-1-1 1-4 6-4 6 3 6 4-1 1-1 1zm5-6a3 3 0 1 0 0-6 3 3 0 0 0 0 6"/></svg>)
Peter Moldt
Direktor/Vorstandsmitglied bei
Cardeas Pharma Corp.
Profil
Peter Moldt was the founder of 7TM A, founded in 2000, where the title held was Senior Executive Vice President from 2000 to 2009.
Dr. Moldt was the founder of Curalogic AS, founded in 2004, where the title held was Chief Executive Officer from 2004 to 2009.
Dr. Moldt is currently Director at Cardeas Pharma Corp.
Dr. Moldt is currently Director at ViewPoint Therapeutics, Inc. since 2018.
Former jobs include Chairman at Allakos, Inc.; Chairman at Bolt Biotherapeutics, Inc. from 2016 to 2021; Non-Executive Director at Biotica Technology Ltd.; Director at Cytochroma, Inc.; Director at Thesan Pharmaceuticals, Inc.; Independent Director at Corvus Pharmaceuticals, Inc. from 2015 to 2019; Director-Drug Development at NTG Nordic Transport Group A; Director at Neurokey A; Director at Hemofocus ApS; Director at Strategic Partners A; Director at Arch Oncology, Inc.; Director at ESCAPE Bio, Inc.; Director at Spruce Biosciences, Inc.; Independent Director at Aligos Therapeutics, Inc.; Director at Outpost Medicine, Inc.; Director at Avalyn Pharma, Inc.; Partner at Novo Holdings A from 2009 to 2012; Partner at Novo Ventures (US), Inc. from 2012 to 2024; Partner at Novo Ventures 1 A. Education includes a doctorate from Yale University and a doctorate from Danmarks Farmaceutiske Universitet.
Aktive Positionen von Peter Moldt
| Unternehmen | Position | Beginn |
|---|---|---|
Cardeas Pharma Corp.
 Cardeas Pharma Corp. Pharmaceuticals: MajorHealth Technology Provides drugs for the prevention of ventilator associated pneumonia | Direktor/Vorstandsmitglied | - |
Viewpoint Therapeutics, Inc.
 Viewpoint Therapeutics, Inc. BiotechnologyHealth Technology Develops non-surgical treatments for eye diseases | Direktor/Vorstandsmitglied | 05.03.2018 |
Ehemalige bekannte Positionen von Peter Moldt
| Unternehmen | Position | Ende |
|---|---|---|
Novo Ventures (US), Inc.
 Novo Ventures (US), Inc. Investment ManagersFinance Novo Ventures US invests venture capital in biotechnology and life science companies throughout the US and Europe. Their typical investments are as equity ranging from 1 to 15 million Euro. The firm may invest at any stage of development of a business idea - from seed capital over private placements to IPOs and public companies and they may invest in any part of the world. | Private Equity Investor | 31.01.2024 |
| BOLT BIOTHERAPEUTICS, INC. | Vorsitzender | 15.11.2021 |
| CORVUS PHARMACEUTICALS, INC. | Direktor/Vorstandsmitglied | 28.01.2019 |
Novo Holdings A/S (Denmark)
 Novo Holdings A/S (Denmark) Investment ManagersFinance Functions as an alternative investment manager | Corporate Officer/Principal | 01.05.2012 |
Cytochroma, Inc.
 Cytochroma, Inc. Pharmaceuticals: MajorHealth Technology Develops and markets prescription products for the prevention of vitamin D insufficiency | Direktor/Vorstandsmitglied | 14.02.2012 |
Ausbildung von Peter Moldt
Erfahrungen
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Beziehungen
23
Beziehungen ersten Grades
25
Unternehmen ersten Grades
Herr
Frau
Aufsichtsräte
Führungskräfte
Unternehmensverbindungen
| Private Unternehmen | 25 |
|---|---|
Biotica Technology Ltd.
 Biotica Technology Ltd. Pharmaceuticals: MajorHealth Technology Develops and manufactures pharmaceuticals | Health Technology |
Cytochroma, Inc.
Cytochroma, Inc. Pharmaceuticals: MajorHealth Technology Develops and markets prescription products for the prevention of vitamin D insufficiency | Health Technology |
Cardeas Pharma Corp.
Cardeas Pharma Corp. Pharmaceuticals: MajorHealth Technology Provides drugs for the prevention of ventilator associated pneumonia | Health Technology |
Thesan Pharmaceuticals, Inc.
 Thesan Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Develops and produces novel therapeutics for skin disorders | Health Technology |
Avalyn Pharma Inc.
 Avalyn Pharma Inc. Pharmaceuticals: MajorHealth Technology Operates as a clinical-stage biopharmaceutical company that develops inhaled therapies to treat rare respiratory & interstitial lung diseases | Health Technology |
Corvus Pharmaceuticals, Inc.
 Corvus Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Provides anticancer immuno-oncology drugs | Health Technology |
NTG Nordic Transport Group A/S
 NTG Nordic Transport Group A/S TruckingTransportation Transports goods through truck, ship and aircraft | Transportation |
Novo Holdings A/S (Denmark)
Novo Holdings A/S (Denmark) Investment ManagersFinance Functions as an alternative investment manager | Finance |
Yale University
 Yale University Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Danmarks Farmaceutiske Universitet
 Danmarks Farmaceutiske Universitet Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
7TM A/S
 7TM A/S BiotechnologyHealth Technology Operates as a biotech company that discovers and develops drugs | Health Technology |
Curalogic AS
 Curalogic AS Pharmaceuticals: MajorHealth Technology Developes pharmaceuticals | Health Technology |
Novo Ventures 1 A/S
 Novo Ventures 1 A/S Investment ManagersFinance Novo Ventures invests in companies located in Europe, the United States and Asia. The firm targets companies operating in the fields of health technology, health services, biotechnology and medical specialties sectors. It provides financing for early stage capital requirements. | Finance |
Neurokey A/S
 Neurokey A/S Pharmaceuticals: MajorHealth Technology Develops drugs for the critical care field | Health Technology |
Hemofocus ApS
 Hemofocus ApS Medical SpecialtiesHealth Technology Provides anticoagulant products | Health Technology |
Strategic Partners A/S
 Strategic Partners A/S Pharmaceuticals: MajorHealth Technology Provides therapeutic treatment of of diseases caused by defects in the function and metabolism of proteins | Health Technology |
Arch Oncology, Inc.
 Arch Oncology, Inc. Pharmaceuticals: MajorHealth Technology Operates as a clinical-stage immuno-oncology company that develops biologic therapies for treatment of patients with tumors and hematologic malignancies | Health Technology |
Novo Ventures (US), Inc.
Novo Ventures (US), Inc. Investment ManagersFinance Novo Ventures US invests venture capital in biotechnology and life science companies throughout the US and Europe. Their typical investments are as equity ranging from 1 to 15 million Euro. The firm may invest at any stage of development of a business idea - from seed capital over private placements to IPOs and public companies and they may invest in any part of the world. | Finance |
Allakos, Inc.
 Allakos, Inc. Pharmaceuticals: MajorHealth Technology Operates as a clinical stage biotechnology company that develops innovative therapeutics which target immunomodulatory receptors for the treatment of allergic, inflammatory and proliferative diseases | Health Technology |
Bolt Biotherapeutics, Inc.
 Bolt Biotherapeutics, Inc. Pharmaceuticals: MajorHealth Technology Operates as a clinical-stage immuno-oncology company | Health Technology |
Viewpoint Therapeutics, Inc.
Viewpoint Therapeutics, Inc. BiotechnologyHealth Technology Develops non-surgical treatments for eye diseases | Health Technology |
Outpost Medicine, Inc.
 Outpost Medicine, Inc. Pharmaceuticals: MajorHealth Technology Engages in drug development activities | Health Technology |
ESCAPE Bio, Inc.
 ESCAPE Bio, Inc. BiotechnologyHealth Technology Develops small molecule therapeutics against genetic targets for neurodegenerative disease | Health Technology |
Spruce Biosciences, Inc.
 Spruce Biosciences, Inc. BiotechnologyHealth Technology Operates as biopharmaceutical company which develops novel therapies for endocrine diseases | Health Technology |
Aligos Therapeutics, Inc.
 Aligos Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Develops targeted, curative therapies for hepatologic diseases and viral infections | Health Technology |
